However, an impressive consensus price target is not the only factor that indicates a potential upside in IPSC. This view is strengthened by the agreement among analysts that the company will ...

Century Therapeutics (NASDAQ:IPSC – Get Free Report) is anticipated to issue its quarterly earnings data before the market ...

Investigators in the laboratory of Gemma Carvill, Ph.D., assistant professor in the Ken and Ruth Davee Department of Neurology Division of Epilepsy/Clinical Neurophysiology, have discovered novel ...

Working with a plug-and-play platform that can be applied to multiple therapeutic targets, Cytovia is advancing universal iPSC NK cells and iPSC CAR NK cells. A non-engineered universal candidate ...

DUBLIN--(BUSINESS WIRE)--The "Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, & Forecasts, 2025" report has been added to ResearchAndMarkets.com's offering. Since the ...

The average 12 month price target among brokerages that have issued a report on the stock in the last year is $10.00. A number of research firms recently issued reports on IPSC. Chardan Capital ...

Boost’s proprietary platform allows for the discovery and detailed characterization of targets and pharmacophores ... Boost has developed a proprietary human iPSC platform and cutting-edge ...